Literature DB >> 12381453

Sodium-iodide symporter (NIS)-mediated accumulation of [(211)At]astatide in NIS-transfected human cancer cells.

Sean Carlin1, Robert J Mairs, Phil Welsh, Michael R Zalutsky.   

Abstract

The cellular expression of the sodium iodide symporter (NIS) has been shown to confer iodide-concentrating capacity in non-thyroid cell types. We examined the role of NIS in the uptake of the alpha-particle emitting radiohalide [(211)At]astatide in the UVW human glioma cell line transfected to express NIS. [(211)At]Astatide uptake is shown to be NIS-dependent, with characteristics similar to [(131)I]iodide uptake. These studies suggest [(211)At]astatide as a possible alternative radionuclide to [(131)I]iodide for NIS-based endoradiotherapy, and provide a model for the study of [(211)At]astatide behavior at a cellular level.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12381453     DOI： 10.1016/s0969-8051(02)00332-3

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN： 0969-8051            Impact factor:   2.408


  11 in total

1.  Astatine Radiopharmaceuticals: Prospects and Problems.

Authors:  Ganesan Vaidyanathan; Michael R Zalutsky
Journal:  Curr Radiopharm       Date:  2008-09-01

2.  Efficacy of 99mTc pertechnetate and 131I radioisotope therapy in sodium/iodide symporter (NIS)-expressing neuroendocrine tumors in vivo.

Authors:  Meike L Schipper; Christoph G U Riese; Stephan Seitz; Alexander Weber; Martin Béhé; Tino Schurrat; Nils Schramm; Boris Keil; Heiko Alfke; Thomas M Behr
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-12-08       Impact factor: 9.236

Review 3.  [The sodium-iodide symporter. Pathophysiologic, diagnostic and therapeutic significance].

Authors:  C Spitzweg
Journal:  Internist (Berl)       Date:  2003-04       Impact factor: 0.743

4.  The potential of 211Astatine for NIS-mediated radionuclide therapy in prostate cancer.

Authors:  Michael J Willhauck; Bibi-Rana Sharif Samani; Ingo Wolf; Reingard Senekowitsch-Schmidtke; Hans-Jürgen Stark; Geerd J Meyer; Wolfram H Knapp; Burkhard Göke; John C Morris; Christine Spitzweg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-11       Impact factor: 9.236

5.  Wild-type p53 enhances the cytotoxic effect of radionuclide gene therapy using sodium iodide symporter in a murine anaplastic thyroid cancer model.

Authors:  Yong Jin Lee; June-Key Chung; Joo Hyun Kang; Jae Min Jeong; Dong Soo Lee; Myung Chul Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-01       Impact factor: 9.236

6.  Evaluation of [18F]-tetrafluoroborate as a potential PET imaging agent for the human sodium/iodide symporter in a new colon carcinoma cell line, HCT116, expressing hNIS.

Authors:  Amanda J Weeks; Maite Jauregui-Osoro; Marcel Cleij; Julia E Blower; James R Ballinger; Philip J Blower
Journal:  Nucl Med Commun       Date:  2011-02       Impact factor: 1.690

7.  Synthesis and biological evaluation of [(18)F]tetrafluoroborate: a PET imaging agent for thyroid disease and reporter gene imaging of the sodium/iodide symporter.

Authors:  Maite Jauregui-Osoro; Kavitha Sunassee; Amanda J Weeks; David J Berry; Rowena L Paul; Marcel Cleij; Jasvinder Paul Banga; Michael J O'Doherty; Paul K Marsden; Susan E M Clarke; James R Ballinger; Istvan Szanda; Sheue-Yann Cheng; Philip J Blower
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06-25       Impact factor: 9.236

8.  Targeting Radiotherapy to Cancer by Gene Transfer.

Authors:  R. J. Mairs; M. Boyd
Journal:  J Biomed Biotechnol       Date:  2003

9.  Synthesis of [211At]4-astato-L-phenylalanine by dihydroxyboryl-astatine substitution reaction in aqueous solution.

Authors:  Yoshifumi Shirakami; Tadashi Watabe; Honoka Obata; Kazuko Kaneda; Kazuhiro Ooe; Yuwei Liu; Takahiro Teramoto; Atsushi Toyoshima; Atsushi Shinohara; Eku Shimosegawa; Jun Hatazawa; Koichi Fukase
Journal:  Sci Rep       Date:  2021-06-21       Impact factor: 4.379

10.  Targeted radionuclide therapy with astatine-211: Oxidative dehalogenation of astatobenzoate conjugates.

Authors:  David Teze; Dumitru-Claudiu Sergentu; Valentina Kalichuk; Jacques Barbet; David Deniaud; Nicolas Galland; Rémi Maurice; Gilles Montavon
Journal:  Sci Rep       Date:  2017-05-31       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.